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anti-atherogenic	effects	of	
incretin-based	therapies:	GLP-1	
analogues	and	DPP-4-inhibitors
Manfredi Rizzo†, Ali A Rizvi, Giatgen A Spinas, Giovam Battista Rini &  
Kaspar Berneis
†University of Palermo, Department of Clinical Medicine and Emerging Diseases,  
Via del Vespro, 141, 9012, Palermo, Italy
Background: Type 2 diabetes is a chronic, progressive disease with a multi-
faceted pathophysiology. Beyond the known defects of insulin resistance and 
β-cell insufficiency, derangement of incretin hormones normally produced 
from the gut wall in response to food intake play an important role. In recent 
years, the ‘incretin-based’ therapies (IBTs) have been developed to address 
hyperglycemia through either mimicking the action of the endogenous 
incretin glucagon-like polypeptide (GLP-1) (GLP-1 receptor agonists) or by 
inhibiting the activity of the enzyme that degrades GLP-1 (the dipeptyl 
peptidase-4 inhibitors). Objective: We reviewed available evidence on the 
glucose lowering and anti-atherogenic effects of IBT. Results: In addition to 
their glucose-lowering and weight-neutral or weight-reducing actions, IBT 
decrease systolic blood pressure and improve fasting and postprandial lipid 
parameters by reducing total-cholesterol, low-density lipoprotein-cholesterol 
and triglycerides concentrations, and increasing high-density lipoprotein-
cholesterol values. Reduced high-sensitivity C-reactive protein levels and 
improved endothelial dysfunction have been reported too. Conclusions: IBT 
have several beneficial effects on cardiovascular risk factors and, for this 
reason, it has been recently suggested to extend the use of these drugs in 
diabetic patients with cardiovascular complications. Yet, the long-term effects 
of IBT on subclinical or clinical atherosclerosis remain to be established by 
future studies.
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1.	 Introduction
Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance, a steady 
impairment in glucose-induced insulin secretion caused by a progressive decrease 
in β-cell function and inappropriately regulated glucagon secretion. These 
pathophysiologic defects result in persistent hyperglycemia and an increased risk 
of both microvascular and cardiovascular complications. Traditional treatments for 
T2D have used oral agents in a stepwise manner, followed by insulin therapy. 
Unfortunately, this approach does not address the progressive decline in β-cell 
function and is often associated with undesirable weight gain. In the past few years, 
new drugs that act by modulating the gut-based incretin system of hormones have 
been introduced for the management of hyperglycemia in T2D. These medications, 
collectively known as incretin-based therapies (IBTs), act by either mimicing the 
actions of glucagon-like polypeptide-1 (GLP-1) or by inhibiting its enzymatic 
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degradation, thus, prolonging its action. These novel agents 
offer the potential of reducing body weight or preventing weight 
gain while lowering glucose levels. Although promising, the 
durability of these effects and their long-term clinical benefits 
needs to be further elucidated. The impact of incretin-based 
treatments on atherosclerotic risk factors (such as blood pres-
sure and plasma lipids) is also under investigation. Substantial 
evidence demonstrates that the GLP-1 receptor agonists and 
dipeptyl peptidase-4 (DPP-4) inhibitors produce modest 
reductions in systolic blood pressure and, in some cases, 
diastolic blood pressure. Reductions in the triglyceride level and 
significant improvements in total, low-density lipoprotein 
(LDL)- and high-density lipoprotein (HDL)-cholesterol have 
also been observed. These effects on cardiovascular risk factors 
are exciting potential beneficial features of IBT. The glucose-
lowering and potential anti-atherogenic actions of these 
medications are the subject of this review article.
2.	 The	‘incretin’	concept
Incretins are hormones produced by the gastrointestinal tract 
in response to oral food ingestion. They help to maintain glu-
cose homeostasis through their coordinated effects on islet α 
and β cells, thereby, inhibiting glucagon output and stimu-
lating insulin secretion in a glucose-dependent manner [1]. 
GLP-1, the predominant incretin hormone, is produced by the 
L cells of the ileum, while glucose-dependent insulinotropic 
polypeptide (GIP) is produced by the K cells in the jejunum. 
In addition to their actions on endocrine pancreatic function, 
both GLP-1 and GIP appear to have local and CNS effects 
that slow gastric emptying and decrease appetite (Table 1). 
The ‘incretin effect’ is diminished or lost over time in people 
with T2D (Figure 1). Although GLP-1 has marked benefits in 
patients with T2D, native GLP-1 administration as a treatment 
strategy is severely limited by a short half-life in vivo due to 
Table	1.	Characteristics	of	the	incretin	hormones	GLP-1	
and	GIP.
GLP-1: secreted by ‘L’ cells in the ileum and colon
GIP: secreted by ‘K’ cells in the duodenum
Stimulation of glucose-dependent insulin release from the 
pancreas
Suppression of glucose output from the liver by glucose-dependent 
inhibition of glucagons secretion (GLP-1 only)
Enhanced β-cell proliferation and survival in animal models and 
human islet cell lines
Retardation of gastric emptying leading to early satiety
Inactivation by dipeptidyl peptidase-4 enzyme and elimination by 
the kidneys
Central suppression of appetite (GLP-1 only)
Reduction of fasting glucose (GLP-1 only)
GIP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide-1.
inactivation by DPP-4 and the impracticality of continuous 
infusion. Thus, pharmacologic strategies have evolved to 
overcome these limitations, either directly by modifying native 
GLP-1 to make it resistant to the effects of DPP-4 or indirectly 
by inhibiting the action of DPP-4. Therefore, new treatments 
for T2D have been introduced recently that utilize the natural 
glucoregulatory effects of incretin hormones [2]. These ‘incretin 
enhancers’ are pharmacologic agents that explore a physiologic 
approach to the management of T2D while limiting some of 
the undesirable side effects such as hypoglycemia and weight 
gain [3,4]. They lower hemoglobin A1c (A1c), body weight 
and postprandial glucose excursions. Animal studies have 
demonstrated improvements in β-cell function in vivo [5].
In April 2005, the FDA approved the first incretin mimetic, 
exenatide, a GLP-1 receptor analogue resistant to DPP-4 
degradation, as adjunctive therapy for patients with T2D. 
Because the GLP-1 analogues (also known as ‘GLP-1 agonists’ 
or ‘mimetics’), require injection, considerable effort has been 
devoted to creating an oral agent targeting the incretin path-
way. Inhibition of DPP-4 extends the half-life of native 
incretins, thereby, prolonging their effects. In October 2006, 
the FDA approved the first oral incretin enhancer, sitagliptin, 
a selective DPP-4-inhibitor, for use as monotherapy or in 
combination with metformin or thiazolidinedione. Additional 
incretin-based agents are also in late-stage development.
Exenatide mimics the actions of endogenous GLP-1 when 
given subcutaneously by injection, while sitagliptin and vilda-
gliptin are agents that inhibit the enzyme DPP-4 responsible 
for degradation of GLP-1 and other incretins. IBT is used 
adjunctively in patients with T2D who fail to achieve glucose 
targets with oral agents. Sitagliptin and vildagliptin can also 
be used as monotherapy in patients T2D uncontrolled by diet. 
The latter medication has been approved in the EU but not 
in all other countries, such as the US. Once-weekly exenatide 
and once-daily liraglutide are other mimetics in development. 
Recent evidence appears to suggest that the salutary effects 
of IBT extend beyond glucose metabolism; thus, a stabiliza-
tion of body weight and beneficial actions on lipids and 
blood pressure may exert a combined anti-atherogenic profile. 
These and other potential actions are summarized in Table 2 
and discussed in the following sections.
3.	 Effects	on	glucose	metabolism
A wealth of data has been accumulated on the use of incretin 
mimetics and DPP-4 inhibitors in the treatment of T2D. 
Their actions predominantly target postprandial hyperglycemia. 
A critical review of Phase III clinical trials of exenatide, sita-
gliptin and vildagliptin [6] showed that the use of exenatide was 
associated with reduction in A1c levels of ∼ 0.8% compared 
with baseline, while sitagliptin or vildagliptin lowered average 
A1c by 0.7%. Treatment-related hypoglycemia was generally 
mild, occurring mainly in combination with sulfonylureas 
(SUs). Exenatide treatment leads to a weight loss of around 
2 kg at 30 weeks, whereas sitagliptin and vildagliptin 
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have neutral effect on weight. About 5 – 10% of patients have 
adverse effects of abdominal fullness, nausea and vomiting. 
Dose-dependent nausea dissipates over time and is atten-
uated by slow titration during initiation of therapy. 
Sitagliptin and vildagliptin are generally well tolerated. In 
short, exenatide, sitagliptin and vildagliptin are useful as 
add-on agents for T2D that is suboptimally controlled with 
oral agents, particularly when there is concern about weight 
Suppressed post-prandial
glucagon decreased
glucose output
Enhanced
insulin
secretion
Liver Pancreas
Incretin release
(GLP-1, GIP, others)
Food
Slowed
gastric
emptying
Increased
satiety
Figure	1.	 The	 incretin	 effect:	 various	actions	of	 the	 incretin	hormones	 (GLP-1	and	other	gut	hormones)	 released	by	 the	
gastrointestinal	tract	in	response	to	food	ingestion. This ability is lost in type 2 diabetes.
GIP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide-1.
Table	2.	Potential	cardiovascular	benefits	of	therapy	with	
incretin	mimetics	and	enhancers	(as	modified	from	[33]).
Reduced fasting/postprandial hyperglycemia and glycoslylated 
hemoglobin
Improved fasting lipid parameters: reduced total- and  
LDL-cholesterol, triglycerides and increased HDL-cholesterol
Improved postprandial dyslipidemia
Reduced high-sensitivity C-reactive protein
Lowered systolic and diastolic blood pressure
Improved endothelial dysfunction in type 2 diabetic patients with 
established coronary heart disease
Improved left ventricular function in acute myocardial infarction
HDL: High-density lipoprotein; LDL: Low-density lipoprotein.
gain and hypoglycemia, or when postprandial hyperglycemia 
is predominant.
The higher the initial A1c, the more pronounced is the 
glucose-lowering effect of IBT. In twice-daily doses of 5 or 
10 μg for 30 weeks, exenatide lowered the A1c by 1.7% in 
the group with a baseline A1c of 9.0% or greater, compared 
with 0.7% for those with a baseline A1c < 9% [7]. Interestingly, 
the difference was sustained with reductions of 2.0 and 
0.8%, respectively, at 82 weeks. The addition of liraglutide 
to metformin, glimepiride, or both, for 26 weeks resulted 
in a greater glucose reduction with increasing A1c [8]. Patients 
in the upper quartile (mean baseline A1c 9.5 – 9.8%) 
experienced a reduction in the A1c of 1.3 – 1.8% com-
pared with 0.5 – 0.9% for those in the lowest quartile 
(mean baseline A1c 7.2 – 7.3%). The challenges and feasi-
bilities of replacing SU with IBT in patients with T2D 
have been addressed as well [9]. SUs can cause weight gain 
and increase the risk of hypoglycemia. They are thought to 
be associated with accelerated β-cell apoptosis, suggesting 
that they may actually promote the progressive decrease in 
β-cell mass and the need for insulin replacement. In con-
trast, the β-cell-preserving properties of IBT potentiate 
glucose-stimulated insulin secretion in T2D. The insulino-
tropic effects of IBT are glucose-dependent, minimizing the 
risk of hypoglycemia.
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Administration of insulin in T2D can roughly mimic 
physiologic insulin secretion when used in a basal-bolus 
fashion. However, it does not address the underlying 
pathophysiology, and hypoglycemia is a potential barrier to 
treatment adherence and glycemic control. Weight gain can 
exacerbate hyperglycemia or insulin resistance. The potential 
of IBT for limiting weight gain while controlling glucose is 
in contrast to insulin [10]. In a 52-week comparison study, 
the addition of exenatide lowered fasting glucose and A1c 
(mean, -1.04%) similar to twice daily biphasic aspart insulin 
when added to a stable regimen of metformin/SU [11] while 
achieving a greater reduction in postprandial glucose and a 
weight loss of 5.4 kg. It follows that when oral agents have 
failed to maintain adequate glycemic control, IBT may be 
particularly well suited to the treatment of T2D patients who 
are overweight or obese with primarily post-meal glucose 
peaks. Exenatide therapy has been proposed as an alternative to 
insulin in patients with treatment failure with either metformin 
monotherapy or metformin–SU combination [10]. The exact 
place of IBT plus available oral antidiabetic agent treatment 
remains an area of ongoing study [12,13].
Liraglutide is a new GLP-1 agonist that shares considerable 
amino-acid homology with human GLP-1. Structural modi-
fications, primarily the addition of a palmitate side chain, 
allow for greater self-association, albumin-binding to albumin, 
prolonged absorption and resistance to inactivation by the 
enzyme DPP-4. A 26-week, double-blind trial demonstrated 
the noninferiority of liraglutide compared to glimepiride in 
a cohort of overweight patients with T2D inadequately con-
trolled with metformin monotherapy [14]. Other studies have 
demonstrated the beneficial effects of liraglutide on weight 
and body composition [15,16].
The family of oral DPP-4 inhibitors has actions on post-
prandial as well as fasting glucose levels. Sitagliptin is approved 
as monotherapy or as adjunct to metformin and SUs in the 
treatment of T2D, lowering A1c by a mean of -0.74% com-
pared with placebo in a 24-week monotherapy trial without 
causing significant nausea or vomiting [17]. A similar but more 
modest effect from baseline was observed with the addition 
of sitagliptin to pioglitazone over a 24 week period [18]. 
Vildagliptin has also shown efficacy as monotherapy in clinical 
studies [19,20]. In drug-naive patients, vildagliptin 50 mg twice 
daily decreased the A1c by 1.3%, similar to rosiglitazone 8 mg 
daily. In patients with a baseline mean A1C of 10%, the 
reductions were 1.8 and 1.9%, respectively [21]. Alogliptin, 
still in development, has yielded similar results in patients who 
were inadequately controlled with lifestyle changes [22].
A recent meta-analysis of randomized controlled trials [13] 
showed that IBT with GLP-1 analogues or DPP-4 inhibitors 
in adults with T2D is effective in improving glycemia, with 
greater reductions in postprandial glycemia and favorable 
(GLP-1 analogues) or neutral (DPP-4 inhibitors) effects on 
weight. Regarding adverse events, glucagon-like peptide 1 ana-
logues were associated with gastrointestinal adverse effects, while 
DPP-4 inhibitors had a slightly increased risk of infection 
(nasopharyngitis and urinary tract infection) and headache. 
Further, in the few available trials, incretin-based medications 
were found to be not inferior compared with non–incretin-
based pharmacologic therapies, including insulin glargine or 
biphasic aspart, glimepiride, metformin, glipizide or thiazo-
lidinediones, with the exception of metformin being superior 
to vildagliptin [13]. Additional trials comparing IBTs with 
existing therapies are also ongoing.
4.	 Effects	on	body	weight
Infusions of GLP-1 reduce gastric emptying, increase satiety 
and mitigate hunger in clinical studies in both healthy volun-
teers and patients with T2D [23]. IBT has glucose-lowering 
actions that are associated with lack of weight gain and even 
weight loss. GLP-1 agonists have the potential to induce sig-
nificant weight reduction concurrently with improved glycemic 
control, while DPP-4 inhibitors exhibit a weight-neutral 
profile [13]. The weight is lost from visceral fat, is mediated 
by gastrointestinal and CNS effects, and appears to be durable 
as long as therapy is continued. The actual amount of weight 
change, however, is variable; some individuals lose impressive 
amounts of weight, while others lose little or none at all. 
Although nausea and vomiting can occur in a subset of patients 
with GLP-1 agonist therapy, the weight loss is not thought 
to be directly attributable to these side effects. No difference 
in the degrees of weight loss has been observed in patients 
who experience gastrointestinal symptoms compared to those 
who do not. Some of the weight-reducing properties of IBT 
have been alluded to in the preceding section.
A succession of three studies evaluated the addition of 
exenatide 10 μg twice daily to SU, metformin or a combina-
tion of SU–metformin therapy. Weight loss ranged from a 
mean -1.6 to -2.8 kg over a 30-week period, and A1c levels 
were lowered from a mean -0.78 to -0.86% [24-26]. The 
weight loss with exenatide was gradual, dose-dependent and 
without an apparent plateau. Similar results have accrued from 
combination studies of exenatide to thiazolidinediones [27]. 
Extension studies have suggested continued weight loss in a 
subset of these patients. Interestingly, trials with a longer-acting 
preparation of exenatide (exenatide LAR) administered once 
weekly have demonstrated a different dose response for the 
glucose-lowering properties compared with the effect on body 
weight [28]. It appears that higher doses are required to obtain 
a robust and sustained reduction in weight. By 15 weeks of 
therapy, there was a 3.8-kg reduction in body weight in 
subjects treated with the highest dose.
The LEAD (Liraglutide Effect and Action in Diabetes) 
program represents a large series of studies undertaken in 
∼ 4200 patients to characterize the effect of liraglutide over 
the spectrum of T2D. Studies were performed with liraglutide 
as monotherapy, in combination with metformin, in combi-
nation with an SU, in combination with metformin and a 
thiazolidinedione, and in combination with metformin plus 
an SU [14,29,30]. A1c reductions were seen in each of these 
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clinical situations. A significant reduction in body weight was 
also observed in all arms except for the combination with SU. 
The magnitude of the weight loss was modest – ∼ 2 – 3 kg 
over a 26-week period – but it appeared to be sustained over 
the duration of the trials (52 weeks) [31]. The greatest weight 
reduction occurred in those with the highest body mass 
index. A1c lowering was generally independent of the weight 
loss, except in individuals treated with metformin and lira-
glutide, in whom there was a correlation between greater A1c 
improvement and the greatest decrease in body weight. Both 
visceral and subcutaneous adipose tissue mass decreased with 
the weight loss along with amelioration in hepatic steatosis and 
reduction in waist circumference. An interesting reduction 
in systolic blood pressure of up to 6 mmHg was observed in 
the liraglutide-treated individuals that did not appear to be 
related to the weight loss [32].
5.	 Effects	on	blood	pressure
Beyond the positive effects on glucose metabolism and body 
weight, the incretin enhancers seem to have beneficial effects 
on blood pressure and blood lipids that may contribute to 
reduced cardiovascular risk [33]. In general, modest reductions 
in blood pressure are observed with both GLP-1 receptor 
agonists and DPP-4 inhibitors. Although modest, such reduc-
tions may be of significant clinical significance in patients 
with T2D. Note that the National High Blood Pressure 
Education Program Coordinating Committee in the latest 
report on prevention, detection, evaluation and treatment 
of high blood pressure has stated that each increment of 
20/10 mmHg above 115/75 mmHg doubles the risk of 
cardiovascular disease [34].
In a retrospective study, therapy with exenatide (5 μg twice 
daily for 26 weeks) in 38 obese patients not controlled with 
oral hypoglycemic agents and insulin led to a reduction in the 
systolic blood pressure (-9.2 mmHg, p = 0.02) [35]. Similar 
findings were obtained by another study that examined the 
long-term effects of exenatide (5 – 10 μg twice daily for 
82 weeks) in overweight metformin-treated individuals; the 
reduction was found in both diastolic and systolic blood 
pressure (-4.1 and -6.3 mmHg, respectively, p < 0.05 for 
both) [36]. Other studies have investigated the effects of lira-
glutide on blood pressure. In a double-blind placebo-controlled 
study, liraglutide as monotherapy at different doses in 
163 diabetic subjects for 14 weeks was able to significantly 
improve systolic blood pressure (up to 7.9 mmHg with the 
maximum dose of 1.9 mg daily); in addition, in relation to 
placebo, the mean diastolic blood pressure decreased signifi-
cantly by 2 – 3 mmHg with all liraglutide doses [36]. The 
LEAD studies have further shown the beneficial effects of 
26 weeks of therapy with liraglutide on blood pressure 
levels [37]. It should be also noted that, in general, the reduc-
tions in blood pressure seen with exenatide and liraglutide 
administration were not due to weight loss. Finally, sitagliptin 
significantly reduced blood pressure in a pilot study of 
19 non-diabetic subjects with mild to moderate hypertension 
(9 on monotherapy and 10 on combination antihypertensive 
therapy), randomized to sitagliptin 50 or 100 mg or placebo 
twice daily for 5 days [38].
6.	 Effects	on	lipid	profile
Several studies have investigated the impact of therapy of incre-
tin enhancers on the lipid profile in patients with T2DM. 
Regarding DPP-4 inhibitors, sitagliptin has been found 
beneficial as both monotherapy and as combination therapy. 
Administered at doses of 5, 12.5, 25 or 50 mg twice daily 
for 12 weeks in subjects who were either drug-naive or on oral 
monotherapy (except a thiazolidinedione) [39], sitagliptin at 
doses greater than 5 mg reduced triglyceride levels by 9 – 14% 
and increased HDL-cholesterol concentrations by 4% compared 
to placebo (p < 0.05 for both).
Other authors have studied the effects of sitagliptin on 
plasma lipids in combination with metformin, pioglitazone, 
glimepiride and glipizide. When added to pre-existing 
metformin therapy (< 1500 mg/day), sitagliptin at doses of 
100 mg/day for 24 weeks resulted in a small but significant 
decrease in levels of total cholesterol, triglycerides and non-
HDL-cholesterol, and a small but significant increase in 
HDL-cholesterol concentration compared with the metformin 
arm (Table 3) [40]. The study was continued for an addi-
tional 80 weeks and results of an interim analysis at 54 weeks 
suggest a sustained reduction in triglycerides and HDL-
cholesterol levels with sitagliptin use [41]. In another study, 
sitagliptin added to on-going pioglitazone therapy (30 or 
45 mg/day) at doses of 100 mg/day for 24 weeks led to a 
significant decrease in levels of plasma triglycerides, while no 
significant differences were noted in the other lipid parameters 
(Table 3) [18]. Finally, in an active controlled study evaluating 
sitagliptin 100 mg versus glipizide 5 mg day added to met-
formin for 52 weeks, the former resulted in a greater increase 
in HDL-cholesterol concentrations (3.7 versus 1.2%) [42].
Vildagliptin also improved plasma lipid parameters in 
patients with metformin-resistant T2D. Patients were ran-
domized to vildagliptin (50 mg twice daily) or pioglitazone 
(30 mg daily) for 24 weeks [43]. Compared to pioglitazone, 
vildagliptin reduced total and LDL-cholesterol by 7 and 10%, 
respectively (p < 0.001 for both); by contrast, triglycerides 
reduced more and HDL-cholesterol increased more after pio-
glitazone than vildagliptin (10 versus 1%, p = 0.004 and 
15 versus 1%, p < 0.001, respectively). Similar results have 
been observed when compared to rosiglitazone, although the 
reduction in triglyceride concentrations with vildagliptin was 
higher (14%) than in the comparison with pioglitazone [21].
Regarding the GLP-1 receptor agonists, exenatide (5 μg 
twice daily, for a mean of 26 weeks) led to a reduction in 
total cholesterol of 8.5% (p = 0.03) and in triglycerides of 26% 
(p = 0.01) when added in obese patients with T2D not 
controlled with oral hypoglycemic agents and insulin [35]; 
notably, in this retrospective study, no changes in plasma 
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lipids were observed in those patients who discontinued 
exenatide. In addition, in overweight patients failing to achieve 
glycemic control with maximal doses of metformin, exenatide 
(5 – 10 μg twice daily for 82 weeks) significantly reduced total 
and LDL-cholesterol and triglyceride levels, with a concomitant 
increase in HDL-cholesterol concentration. These improvements 
in plasma lipids were independent of weight loss [36].
Liraglutide also significantly improved triglyceride concen-
trations in a 14-week study performed in patients inade-
quately controlled on oral antihyperglycemic monotherapy [29]: 
triglycerides significantly decreased by 19 and 22% with doses 
of liraglutide of 0.65 and 1.9 mg versus placebo (p = 0.0304 
and 0.0110, respectively). Similarly, in another study investi-
gating the addition of exenatide or liraglutide to oral antihy-
perglycemic therapy, triglyceride concentrations improved more 
in patients treated with liraglutide than exenatide [44].
Other authors have reported the effects of incretins 
enhancers on postprandial lipemia (as reviewed in [45]). In a 
pilot study [46], treatment with GLP-1 was associated, post-
prandially, with reduced VLDL triglycerides, while LDL- and 
HDL-cholesterol concentrations were unchanged; notably, 
GLP-1 increased LDL particle diameter as compared to the 
control group. Similarly, postprandial triglycerides were 
reduced in another study investigating the effects of acute 
GLP-1 administration in healthy volunteers [47]. Matikainen 
et al. [48] investigated in a randomized, double-blind, placebo-
controlled study the effect of vildagliptin (50 mg twice daily 
for 4 weeks) on postprandial lipemia in T2D; vildagliptin 
reduced postprandial levels of total triglycerides and those 
contained in triglyceride-rich lipoproteins.
7.	 Conclusion
The incretin concept, as it is currently understood, dates 
back to early observations that ingested glucose results in a 
Table	3.	Effects	of	sitagliptin	(100	mg/day)	added	to	
metformin	(<	1500	mg/day)	or	pioglitazone		
(30	or	45	mg/day)	on	plasma	lipids	after	24	weeks	[18,40].
Sitagliptin	+	
metformin		
(n	=	429)
Sitagliptin	+	
pioglitazone	
(n	=	151)
Total-cholesterol (mg/dl) -2.8%* 0.0%
Triglycerides (mg/dl) -16.9%‡ -11.2%*
HDL-cholesterol (mg/dl) 2.0%* 0.2%
LDL-cholesterol (mg/dl) -0.8% 3.3%
Non-HDL-cholesterol -4.8%* 0.4%
*p < 0.05.
‡p < 0.001.
Data are expressed as placebo-subtracted least squares mean % change from 
baseline (95% CI).
HDL: High-density lipoprotein; LDL: Low-density lipoprotein.
considerably larger and more sustained insulin response than 
glucose administered intravenously. Impairments in the incretin 
response in patients with T2D may contribute to dysregula-
tion of insulin and glucagon secretions, particularly during 
the postprandial period, thus, leading to hyperglycemia. The 
recent introduction in the market of the new antidiabetic 
drugs modulating the incretin system, such as the GLP-1 
receptor agonists and the DPP-4 inhibitors, may open new 
horizons in the management of T2D.
In addition to their glucose-lowering and weight-neutral or 
weight-reducing actions, substantial evidence demonstrates 
that the GLP-1 receptor agonists and DPP-4 inhibitors pro-
duce decreases in systolic blood pressure and, in some cases, 
diastolic blood pressure. Furthermore, IBT has been shown 
to improve fasting and postprandial lipid parameters by 
reducing total cholesterol, LDL-cholesterol and triglycerides 
concentrations, and increasing HDL-cholesterol values. 
Improved endothelial dysfunction in T2D patients with 
established coronary heart disease have been reported with 
GLP-1 [49] and reduced high-sensitivity C-reactive protein 
levels with exenatide administration was found in subjects 
with T2D [50]. Due to these beneficial actions on cardiovascular 
risk factors, it has been recently suggested using these drugs 
in diabetic patients with cardiovascular complications (as 
reviewed in [51]). Yet, the long-term effects of therapies with 
GLP-1 receptor agonists and DPP-4 inhibitors on subclinical 
(e.g., increased carotid intima-media thickness) or clinical 
(e.g., cardiovascular morbidity and mortality) atherosclerosis 
remain to be established by future studies.
8.	 Expert	opinion
The recent introduction in the market of the new antidiabetic 
drugs modulating the incretin system has opened new hori-
zons in the management of T2D. The incretin concept dates 
back to early observations that ingested glucose results in a 
considerably larger and more sustained insulin response than 
glucose administered intravenously. Two incretins have been 
identified within the gastrointestinal tract with the property 
of stimulating insulin release: GIP and GLP-1. Impairments 
in the incretin response may contribute to dysregulation of 
insulin and glucagon secretion, particularly during the 
postprandial period, leading to hyperglycemia.
Although GLP-1 given experimentally has marked benefits 
in patients with T2D, native GLP-1 administration, as a treat-
ment strategy, is severely limited by a short half-life in vivo 
due to inactivation by DPP-4 and the impracticality of con-
tinuous infusion. Thus, pharmacologic strategies have evolved 
to overcome these limitations, either directly by modifying 
native GLP-1 to make it resistant to the effects of DPP-4 
(GLP-1 mimetics and analogues) or indirectly (by inhibiting 
the action of DPP-4).
A recent meta-analysis of randomized controlled trials showed 
that IBT with GLP-1 analogues or DPP-4 inhibitors in adults 
with T2D are effective in improving glycemia, with greater 
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reductions in postprandial glycemia and favorable (GLP-1 
analogues) or neutral (DPP-4 inhibitors) effects on weight. 
Regarding adverse events, glucagon-like peptide 1 analogues 
were associated with gastrointestinal adverse effects, while 
DPP-4 inhibitors had a slightly increased risk of infection 
(nasopharyngitis and urinary tract infection) and headache. 
Further, in the few available trials, incretin-based medications 
were found to be not inferior compared with non-incretin-
based pharmacologic therapies, including insulin glargine or 
biphasic aspart, glimepiride, metformin, glipizide or thiazo-
lidinediones, with the exception of metformin being superior 
to vildagliptin. Additional trials comparing IBTs with existing 
therapies are also ongoing.
The appealing aspect of these agents lies in their weight-
neutral or even weight-reducing effects concurrent with their 
glucose-lowering actions. Preliminary data suggest that IBTs 
may preserve β-cell function in the long-term, thus, promising 
to be disease-modifying drugs. Using these agents early in 
the diabetic process may indeed be effective in preventing 
the disease or retarding its progression. The GLP-1 receptor 
agonists could be particularly beneficial in overweight or obese 
patients who have cardiovascular risk factors. In particular, 
there is promising evidence that IBTs have salutary effects 
on blood pressure and lipid profile. Through beneficial 
actions on the risk factors that often cluster in individuals 
with diabetes (obesity, hyperglycemia, hypertension and dys-
lipidemia), incretin-based treatments may potentially reduce 
cardiovascular morbidity and mortality from this devastating 
disease. This needs to be tested by future prospective studies 
and will probably become one of the ‘hot topics’ in diabetes 
and cardiovascular prevention in the next few years.
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